MedPath

A New Supplement for the "Metabolic Syndrome"

Not Applicable
Completed
Conditions
Metabolic Syndrome
Interventions
Dietary Supplement: Sineos
Registration Number
NCT03813914
Lead Sponsor
University of Messina
Brief Summary

This study evaluates the effect of a combination of glycirrhizic acid, Cinnamomun Zeylanicum and corosolic acid for the treatment of metabolic syndrome. Participants receive the supplement or a placebo.

Detailed Description

The supplement is composed by of a combination of glycirrhizic acid, Cinnamomun Zeylanicum and corosolic acid. They act in different way reducing insulin resistance, which is the main cause of metabolic syndrome. It was a randomized, controlled study involving 60 women with the metabolic syndrome following the criteria proposed by ATP III in 2015. Main outcomes were the improvement of the parameters that characterizes the metabolic syndrome, such as glucose and insulin levels, triglycerides, HDL-cholesterol and blood pressure.

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
60
Inclusion Criteria

Postmenopausal women affected by Metabolic Syndrome, diagnosed by ATP 2015 criteria.

Exclusion Criteria

treatment with steroids or with hypoglycemic or anti-cholesterol drugs

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
SineosSineosGlycyrrhizic acid 38 mg + Cinnamomum Zeylanicum 150 mg + corosolic acid 480 mcg 2 pills/day for 3 months
Placebo comparatorSineosplacebo 2 pills/day for 3 months
Primary Outcome Measures
NameTimeMethod
Changes in glycemia3 months

Reduction of glycemia (mg/dl)

Changes in HDL-cholesterol3 months

Increase of HDL-C (mg/dl)

Secondary Outcome Measures
NameTimeMethod
changes in total-cholesterol3 months

reduction of cholesterol (mg/dl)

changes in triglycerides3 months

reduction in triglycerides (mg/dl)

changes in HOMA-IR3 months

measured as the ratio between glycaemia (mg/dl) and insulin (UI)

© Copyright 2025. All Rights Reserved by MedPath